BioNTech and Gilead Sciences Announce Clinical Collaboration for Breast Cancer Treatment

BioNTech SE and Gilead Sciences have entered into a clinical trial collaboration and supply agreement to evaluate a new combination therapy for locally advanced or metastatic triple-negative breast cancer (TNBC). The trial will test BioNTech’s Pumitamig alongside Gilead’s Sacituzumab Govitecan as a first-line treatment. This partnership aims to enhance treatment outcomes for patients with TNBC by leveraging the expertise of both companies in oncology.